Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors
Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8
Pliant got special permission from the FDA to test a new cancer medicine faster than usual. This is a sign the medicine looks promising, so people are watching to see if the company's drug actually helps patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.